GlaxoSmithKline Biologicals (GSK) is one of the world's leading vaccine companies, involved in vaccine research, development and production. We have 15 vaccines in development and our broad portfolio of 39 vaccines prevent illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Globally, we have more than 16,000 people working to deliver nearly 2 (1.9) million vaccines every day to people in around 90% (172) of the world's countries. In 2015 we distributed around 690 million doses of vaccine, over 70% of them to less developed, low and middle income countries.
The role of GSK in the VAC2VAC project
GlaxoSmithKline Biologicals (GSK) is one of the industry partners of VAC2VAC contributing as member of the scientific management team and bringing the biggest in-kind contribution made available for the project. GSK is supporting, through its internal expertise, the development, optimisation and evaluation of physicochemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines according to the Consistency Approach. In addition, GSK will work towards a consensus with regulatory agencies on acceptance of the new methods developed that would significantly reduce the future use of animals for batch testing in routine vaccine production.
GSK's internal Quality and R&D experts on physicochemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines; its experts on Regulatory Affairs and Product Life Cycle Management will work to help to ensure that VAC2VAC reaches its goal.
Denis Lambrigts, Head of Vaccines Global Animal Welfare, Ethics and Startegy, 3 R programme Lead